[1] |
Wong GW, Wang J, Hug C, et al. A family of Acrp30/adiponectin structural and functional paralogs[J]. Proc Natl Acad Sci U S A, 2004, 101(28): 10302-10307.
doi: 10.1073/pnas.0403760101
URL
|
[2] |
Schäffler A, Buechler C. CTRP family: linking immunity to metabolism[J]. Trends Endocrinol Metab, 2012, 23(4): 194-204.
doi: 10.1016/j.tem.2011.12.003
URL
|
[3] |
Li Y, Wright GL, Peterson JM. C1q/TNF-related protein 3 (CTRP3) function and regulation[J]. Compr Physiol, 2017, 3(7): 863-878.
|
[4] |
Peterson JM, Wei Z, Wong GW. C1q/TNF-related protein-3 (CTRP3), a novel adipokine that regulates hepatic glucose output[J]. J Biol Chem, 2010, 285(51): 39691-39701.
doi: 10.1074/jbc.M110.180695
pmid: 20952387
|
[5] |
Maeda T, Jikko A, Abe M, et al. Cartducin, a paralog of Acrp30/adiponectin, is induced during chondrogenic differentiation and promotes proliferation of chondrogenic precursors and chondrocytes[J]. J Cell Physiol, 2006, 206(2): 537-544.
pmid: 16155912
|
[6] |
Li X, Jiang L, Yang M, et al. GLP-1 receptor agonist increases the expression of CTRP3, a novel adipokine, in 3T3-L1 adipocytes through PKA signal pathway[J]. J Endocrinol Invest, 2015, 38(1): 73-79.
doi: 10.1007/s40618-014-0156-8
pmid: 25149084
|
[7] |
Yagmur E, Otto S, Koek GH, et al. Decreased CTRP3 plasma concentrations are associated with sepsis and predict mortality in critically ill patients[J]. Diagnostics, 2019, 9(2): 63.
doi: 10.3390/diagnostics9020063
URL
|
[8] |
Li Y, Ozment T, Wright GL, et al. Identification of putative receptors for the novel adipokine CTRP3 using ligand-receptor capture technology[J]. PLoS One, 2016, 11(10): e164593.
|
[9] |
Schmid A, Kopp A, Hanses F, et al. The novel adipokine C1q/TNF-related protein-3 is expressed in human adipocytes and regulated by metabolic and infection-related parameters[J]. Exp Clin Endocrinol Diabetes, 2012, 120(10): 611.
doi: 10.1055/s-0032-1323803
URL
|
[10] |
Kwon MR, Cress E, Clark WA, et al. The adipokine C1q TNF related protein 3(CTRP3) is elevated in the breast milk of obese mothers[J]. PeerJ, 2018, 6: e4472.
doi: 10.7717/peerj.4472
URL
|
[11] |
Masoodian SM, Toolabi K, Omidifar A, et al. Increased mRNA expression of CTRP3 and CTRP9 in adipose tissue from obese women[J]. Rep Biochem Mol Biol, 2020, 9(1): 71-81.
|
[12] |
Schmid A, Gehl J, Thomalla M, et al. Downregulation of CTRP-3 by weight loss in vivo and by bile acids and incretins in adipocytes in vitro[J]. Int J Mol Sci, 2020, 21(21): 8168.
doi: 10.3390/ijms21218168
URL
|
[13] |
Wolf RM, Steele KE, Peterson LA, et al. Lower circulating C1q/TNF-related protein-3(CTRP3) levels are asso-ciated with obesity[J]. PLoS One, 2015, 10(7): e133955.
|
[14] |
Chen T, Wang F, Chu Z, et al. Serum CTRP3 levels in obese children[J]. Diabetes Metab Syndr Obes, 2019, 12: 1923-1930.
doi: 10.2147/DMSO.S222066
URL
|
[15] |
Wagner RM, Sivagnanam K, Clark WA, et al. Divergent relationship of circulating CTRP3 levels between obesity and gender[J]. PeerJ, 2016, 4: e2573.
doi: 10.7717/peerj.2573
URL
|
[16] |
Choi KM, Hwang SY, Hong HC, et al. C1q/TNF-related protein-3(CTRP-3) and pigment epithelium-derived factor (PEDF) concentrations in patients with type 2 diabetes and metabolic syndrome[J]. Diabetes, 2012, 61(11): 2932-2936.
doi: 10.2337/db12-0217
URL
|
[17] |
Moradi N, Najafi M, Sharma T, et al. Circulating levels of CTRP3 in patients with type 2 diabetes mellitus compared to controls: a systematic review and meta-analysis[J]. Diabetes Res Clin Pract, 2020, 169: 108453.
doi: 10.1016/j.diabres.2020.108453
URL
|
[18] |
Li JY, Wu GM, Hou Z, et al. Expression of C1q/TNF-related protein-3 (CTRP3) in serum of patients with gesta-tional diabetes mellitus and its relationship with insulin resistance[J]. Eur Rev Med Pharmacol Sci, 2017, 21(24): 5702-5710.
|
[19] |
Ma ZG, Yuan YP, Xu SC, et al. CTRP3 attenuates cardiac dysfunction, inflammation, oxidative stress and cell death in diabetic cardiomyopathy in rats[J]. Diabetologia, 2017, 60(6): 1126-1137.
doi: 10.1007/s00125-017-4232-4
URL
|
[20] |
Yan Z, Cao X, Wang C, et al. C1q/tumor necrosis factor-related protein-3 improves microvascular endothelial function in diabetes through the AMPK/eNOS/NO· signaling pathway[J]. Biochem Pharmacol, 2022, 195: 114745.
doi: 10.1016/j.bcp.2021.114745
URL
|
[21] |
Hu TY, Li LM, Pan YZ. CTRP3 inhibits high glucose-induced human glomerular mesangial cell dysfunction[J]. J Cell Biochem, 2019, 120(4): 5729-5736.
doi: 10.1002/jcb.27859
URL
|
[22] |
Peterson JM, Seldin MM, Wei Z, et al. CTRP3 attenuates diet-induced hepatic steatosis by regulating triglyceride metabolism[J]. Am J Physiol Gastrointest Liver Physiol, 2013, 305(3): G214-G224.
doi: 10.1152/ajpgi.00102.2013
URL
|
[23] |
Zhang J, Xu J, Lin X, et al. CTRP3 ameliorates fructose-induced metabolic associated fatty liver disease via inhibition of xanthine oxidase-associated oxidative stress[J]. Tissue Cell, 2021, 72: 101595.
doi: 10.1016/j.tice.2021.101595
URL
|
[24] |
Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397(10290): 2212-2224.
doi: 10.1016/S0140-6736(20)32511-3
pmid: 33894145
|
[25] |
Sun BR, Li HY, Wang GP, et al. C1q/tumor necrosis factor-related protein-3 acts as a target treating hepatic fibrosis[J]. Eur Rev Med Pharmacol Sci, 2021, 25(17): 5374-5382.
|
[26] |
Zhang J, Zhang B, Cheng Y, et al. Low serum CTRP3 levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus[J]. Cytokine, 2018, 106: 131-135.
doi: S1043-4666(17)30337-X
pmid: 29113741
|
[27] |
Zhou W, Wang Y, Wu Y, et al. Serum CTRP3 level is inversely associated with nonalcoholic fatty liver disease: a 3-y longitudinal study[J]. Clin Chim Acta, 2018, 479: 79-83.
doi: S0009-8981(18)30003-2
pmid: 29305845
|
[28] |
Demirtas D, Acıbucu F, Baylan FA, et al. CTRP3 is significantly decreased in patients with primary hyperparathyroidism and closely related with osteoporosis[J]. Exp Clin Endocrinol Diabetes, 2020, 128(3): 152-157.
doi: 10.1055/a-0899-5210
URL
|
[29] |
Maghbooli Z, Hossein-Nezhad A, Khoshechin G, et al. Possible association between circulating CTRP3 and knee osteoarthritis in postmenopausal women[J]. Aging Clin Exp Res, 2019, 31(7): 927-934.
doi: 10.1007/s40520-018-1035-5
pmid: 30191454
|
[30] |
林雪, 张军霞, 徐锦秀, 等. C1q/肿瘤坏死因子相关蛋白3对高尿酸大鼠血管内皮的保护作用研究[J]. 中国病理生理杂志, 2020, 36(9):1551-1556.
|
[31] |
徐锦秀, 张军霞, 向光大, 等. 血清补体C1q/肿瘤坏死因子相关蛋白3与2型糖尿病患者血尿酸水平的关联[J]. 中华疾病控制杂志, 2020, 24(4): 394-398.
|
[32] |
Framnes SN, Arble DM. The bidirectional relationship between obstructive sleep apnea and metabolic disease[J]. Front Endocrinol (Lausanne), 2018, 9: 440.
doi: 10.3389/fendo.2018.00440
URL
|
[33] |
Kilavuz A, Celikhisar H, Dasdemir Ilkhan G. The association of serum 25(OH) vitamin D level with severity of obstructive sleep apnea syndrome in patients with syndrome Z (the interaction of obstructive sleep apnea with metabolic syndrome)[J]. Metab Syndr Relat Disord, 2021, 19(10): 549-555.
|
[34] |
范榕, 白亚丽, 赵雅宁, 等. 血清补体C1q肿瘤坏死因子相关蛋白-3在阻塞性睡眠呼吸暂停低通气综合征加重2型糖尿病患者下肢血管病变中的作用[J]. 中国老年学杂志, 2019, 39(6): 1312-1315.
|